Send to

Choose Destination
Respir Med Case Rep. 2017 May 30;22:7-10. doi: 10.1016/j.rmcr.2017.05.010. eCollection 2017.

EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.

Author information

Pulmonary Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Oncology Department, University General Hospital of Larissa, Larissa, Greece.
Department of Respiratory and Critical Care Medicine, Changhai Hospital, The Second Military Medical University, Shanghai, China.
Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece.
Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.


Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression.


Adenocarcinoma; Anaplastic lymphoma kinase; Epidermal growth factor; NSCLC; Programmed death-ligand 1

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center